Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06424067 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Study of Fingolimod in Lung Cancers

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv9
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v8 Show 1 more changeShow less
    • Study sites: 0 to 1
  3. Start date: Mar 31, 2025 to May 1, 2025 Primary completion date: Mar 31, 2027 to May 1, 2027 · Completion date: Mar 31, 2028 to May 1, 2028v7 Show 2 more changesShow less
    • Primary completion date: Mar 31, 2027 to May 1, 2027
    • Completion date: Mar 31, 2028 to May 1, 2028
  4. Start date: Mar 1, 2025 to Mar 31, 2025 Primary completion date: Mar 1, 2027 to Mar 31, 2027 · Completion date: Mar 1, 2028 to Mar 31, 2028v6 Show 2 more changesShow less
    • Primary completion date: Mar 1, 2027 to Mar 31, 2027
    • Completion date: Mar 1, 2028 to Mar 31, 2028
  5. Start date: Nov 30, 2024 to Mar 1, 2025 Primary completion date: Nov 30, 2026 to Mar 1, 2027 · Completion date: Nov 30, 2027 to Mar 1, 2028v5 Show 2 more changesShow less
    • Primary completion date: Nov 30, 2026 to Mar 1, 2027
    • Completion date: Nov 30, 2027 to Mar 1, 2028
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: May 31, 2026 to Nov 30, 2026 Start date: Sep 30, 2024 to Nov 30, 2024 · Completion date: May 31, 2027 to Nov 30, 2027v4 Show 2 more changesShow less
    • Start date: Sep 30, 2024 to Nov 30, 2024
    • Completion date: May 31, 2027 to Nov 30, 2027
  2. Start date: Jul 31, 2024 to Sep 30, 2024v3
  3. Start date: Jun 1, 2024 to Jul 31, 2024 Study title expanded, about 5 wordsv2 Show 1 more changeShow less
    • Study title expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for efficacy analysis where fingolimod 0.5 mg will be taken orally once daily.
Trial Details
NCT Number NCT06424067
Lead Sponsor Medical University of South Carolina
Conditions Non Small Cell Lung Cancer, Small-cell Lung Cancer
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov